Emergent BioSolutions (EBS) Cash from Investing Activities (2010 - 2026)

Emergent BioSolutions' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$2.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 104.03% year-over-year to -$2.4 million; the TTM figure through Mar 2026 stood at $7.5 million (down 96.16% YoY), while the FY2025 annual figure was $69.4 million, down 44.57% from the prior year.
• Cash from Investing Activities was -$2.4 million for Q1 2026 at Emergent BioSolutions, up from -$3.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $257.7 million in Q2 2023 to a low of -$271.6 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged $1.4 million across 5 years, with a median of -$4.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 392.03% in 2022, then jumped 902.8% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$45.4 million in 2022, then surged by 74.89% to -$11.4 million in 2023, then soared by 350.88% to $28.6 million in 2024, then sank by 113.64% to -$3.9 million in 2025, then soared by 38.46% to -$2.4 million in 2026.
• The last three Cash from Investing Activities figures came in at -$2.4 million (Q1 2026), -$3.9 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.